Paul-Ehrlich-Institut, Department of Virology, Section Viral Vaccines, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany.
Paul-Ehrlich-Institut, Department of Virology, Section Viral Vaccines, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany.
Vaccine. 2018 Apr 19;36(17):2364-2370. doi: 10.1016/j.vaccine.2018.02.078. Epub 2018 Mar 23.
The governmental quality control of human vaccines is a long established tradition in many European countries. In Germany, vaccines have been controlled by a governmental agency since 1935. In the beginning, vaccine production and control was a purely national activity. However, that changed fundamentally in 1994 when the so-called Official Control Authority Batch Release Network (OCABR) was implemented shortly after the establishment of the European Union. Today, Official Medicinal Control Laboratories (OMCLs) are part of the European OCABR Network. In many European countries, OMCLs experimentally test every batch of human vaccines before they enter the market. We wanted to gain insights into the benefits of batch release by the Network and address the question whether batch release is still useful. This question was investigated in the context of influenza vaccines.
Notifications on influenza vaccines circulated from 2006 to 2016 within the OCABR network were compiled and organized into 32 cases. The impact of these findings was evaluated, and the communication pathways between companies and respective European control laboratories were examined.
Approximately 5850 batches were tested by the OMCL network between 2006 and 2016. Among these, notifications belonging to 32 cases were observed. The predominant proportion of the circulated notifications related to manufacturing issues. In most cases, the manufacturer itself had withdrawn the batches before they entered the market. However, in three cases, batches of insufficient quality were detected by the respective European Control Laboratory leading to withdrawal of 13 batches.
13 batches which did not meet the specifications of influenza vaccine were detected by the OMCL network between 2006 and 2016 which would not have been identified by the manufacturer. This demonstrates the impact of governmental batch release. Together with the intrinsic values of the OCABR system and keeping in mind that vaccines are given to healthy often young individuals, governmental batch release of influenza vaccines is still justified.
在许多欧洲国家,政府对人用疫苗的质量控制是一项由来已久的传统。在德国,自 1935 年以来,疫苗一直由政府机构控制。起初,疫苗生产和控制完全是一项国家活动。然而,这种情况在 1994 年发生了根本性的变化,当时在欧盟成立后不久,实施了所谓的官方控制机构批次放行网络(OCABR)。如今,官方药品控制实验室(OMCL)是欧洲 OCABR 网络的一部分。在许多欧洲国家,OMCL 在每批人用疫苗进入市场之前都会进行实验测试。我们想了解网络批次放行的好处,并探讨批次放行是否仍然有用。在流感疫苗的背景下,我们研究了这个问题。
我们汇编并整理了 2006 年至 2016 年 OCABR 网络内流通的流感疫苗通知,共 32 例。评估了这些发现的影响,并研究了公司与各自欧洲控制实验室之间的沟通途径。
在 2006 年至 2016 年期间,OMCL 网络共检测了约 5850 批疫苗。在这些批次中,观察到属于 32 例的通知。流通通知的主要比例与生产问题有关。在大多数情况下,制造商在这些批次进入市场之前已自行撤回。然而,在三个案例中,由于各自的欧洲控制实验室检测到质量不足的批次,导致 13 批疫苗被撤回。
在 2006 年至 2016 年期间,OMCL 网络检测到 13 批不符合流感疫苗规格的批次,而这些批次是制造商无法识别的。这证明了政府批次放行的影响。考虑到 OCABR 系统的内在价值,并且疫苗是给予健康的、通常是年轻的个体的,因此政府对流感疫苗的批次放行仍然是合理的。